EUCTR2016-001331-12-DE进行中（未招募）1 期
A randomized phase II study comparing pembrolizumab with methotrexate in elderly, frail or cisplatin-ineligible patients with head and neck cancers - ELDORANDO
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Cooperation and willingness to complete all aspects of the study including participation in the translational research
- •2.Signed and dated written informed consent must be given prior to study inclusion
- •3.Histological or cytological confirmed recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC) not amenable to local therapies
- •4.Progressive disease at study entry
- •5.At least 1 measurable lesion according to RECIST 1.1
- •6.No previous systemic treatment for metastatic disease
- •7.Not eligible for cisplatin-based chemotherapy, defined as:
- •-calculated CrCl <60 mL/min (measured by MDRD)
- •8.Age = 18 years
- •9.ECOG performance status 0 - 2
- •10.Brain metastases require completion of local therapy with discontinuation of steroids prior to start of treatment
- •11.If of childbearing potential, willingness to use highly effective contraceptive method for the duration of the study and 120 days after last dose, such as combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), vasectomized partner, bilateral tubal occlusion, sexual abstinence. If an oral contraception is used, a barrier method of contraception (e.g. male condom, female condom, cervical cap, diaphragm, contraceptive sponge) has to be applied additionally.
- •12.Adequate bone marrow function, liver and renal function:
- •a.Absolute neutrophil count = 1.5 x 109/L
- •b.Thrombocytes = 100 x 109/L
- •c.Hemoglobin = 9 g/dL
- •d.INR = 1.5 and PPT = 1.5 x lower limit during the last 7 days before therapy
- •e.Bilirubin < 1.5 x lower limit and
- •f.AST (GOT) and ALT (GPT) < 3 x lower limit (5 x lower limit in case of liver metastases)
- •13.Tumor block or 20 slides must be available at study inclusion for central pathology testing
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 70
排除标准
- •1.Live expectancy less than 3 months
- •2.Nasopharynx carcinoma
- •3.Anticancer treatment during the last 30 days prior to start of treatment, including systemic therapy, radiotherapy or major surgery
- •4.Participation in a clinical trial within the last 30 days prior to study treatment
- •5.History of allogeneic tissue/solid organ transplant
- •6.History of pneumonitis that has required oral or i.v. steroids
- •7.Evidence of interstitial lung disease
- •8.Minor surgery = 24 hours prior first dose of study treatment
- •9.Symptomatic acute cardiovascular or cerebrovascular disease
- •10.Known active HBV, HCV or HIV infection
- •11.Has any other active infection requiring systemic therapy.
- •12.Patients with active tuberculosis
- •13.Prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-PD-L1, anti-programmed cell death-ligand 2 (anti-PD-L2), anti-CD137 (4-1BB ligand, a member of the Tumor Necrosis Factor Receptor [TNFR] family), or anti-cytotoxic T-lymphocyte-associated antigen-4 (anti-CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
- •14.A diagnosis of immunodeficiency or patient is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- •15.Patient has had a prior monoclonal antibody, which does significantly interfere with the immune system or which does have a systemic therapeutic effect on the tumor within 4 weeks prior to randomization.
- •16.Patient has not recovered (i.e., = Grade 1 or at baseline) from any toxicities due to agents administered more than 4 weeks earlier. [Subjects with = Grade 2 neuropathy or alopecia are an exception to this criterion and may qualify for the study.]
- •17.Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjorgen’s syndrome will not be excluded from the study.
- •18.Has received a live vaccine within 30 days prior to the first dose of trial treatment.
- •19.Has known hypersensitivity to methotrexate or pembrolizumab or any constituent of the products.
- •20.Other active malignancy requiring treatment
- •21.Lactating or pregnant women, women of child-bearing potential who do not agree to the usage of highly effective contraception methods (allowed methods of contraception, meaning methods with a rate of failure of less than 1% per year combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), vasectomized partner, bilateral tubal occlusion, sexual abstinence. If an oral contraception is used, a barrier method of contraception (e.g. male condom, female condom, cervical cap, diaphragm, contraceptive sponge) has to be applied additionally. Women of childbearing potential must have a negative pregnancy test (serum ß-hCG) at Screening.
- •22.Any psychiatric illness that would affect
研究者
相似试验
终止
2 期
Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck CancersCancer of Head and NeckNCT03193931AIO-Studien-gGmbH47
进行中（未招募）
1 期
A PHASE II/III RANDOMIZED STUDY OF PEMBROLIZUMABIN PATIENTS WITH ADVANCED MALIGNANT PLEURAL MESOTHELIOMAPATIENTS WITH ADVANCED MALIGNANT PLEURAL MESOTHELIOMAMedDRA version: 22.1Level: LLTClassification code 10051930Term: Mesothelioma malignancy unspecifiedSystem Organ Class: 100000004864EUCTR2016-002286-60-ITISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE520
进行中（未招募）
1 期
A PHASE II/III RANDOMIZED STUDY OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED MALIGNANT PLEURAL MESOTHELIOMAMalignant pleural mesotheliomaEUCTR2016-002286-60-GBCanadian Cancer Trials Group390
招募中
2 期
Randomized Phase II, 2-arm study of Pembrolizumab after high dose radiation (SBRT) versus Pembrolizumab alone in patients with advanced non-small cell lung cancer.Non small cell lung cancer10038666lung cancerNL-OMON44895Antoni van Leeuwenhoek Ziekenhuis74
进行中（未招募）
1 期
Pembrolizumab after high dose radiation versus Pembrolizumab alone in patients with non-small cell lung cancer.Advanced non-small cell lung cancerMedDRA version: 19.0Level: LLTClassification code 10025048Term: Lung cancer non-small cell recurrentSystem Organ Class: 100000004864EUCTR2014-005118-49-NLStichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis